Photo from wikipedia
Galectin-3 (gal-3) has recently been shown to mediate insulin resistance in mice. Its deletion leads to insulin sensitization while its excess is associated with insulin resistance. We, thus, undertook an… Click to show full abstract
Galectin-3 (gal-3) has recently been shown to mediate insulin resistance in mice. Its deletion leads to insulin sensitization while its excess is associated with insulin resistance. We, thus, undertook an investigation into its role in the reversal of insulin resistance in three human models of insulin sensitization: (1) 6 months following bariatric surgery (RYGB) and weight loss in patients with morbid obesity; there was a reduction in BMI from 52.1±4.8 to 40.4±4.0 kg/m 2 (p Disclosure P. Dandona: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. H. Ghanim: None. M.S. Shah: None. K. Green: None. A. Makdissi: Speaker9s Bureau; Self; Eli Lilly and Company. A. Chaudhuri: Speaker9s Bureau; Self; AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc..
Journal Title: Diabetes
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!